GlassScriptPhysician profile
Tova Sofer
NPI 1205169083
$4,211.56
in general payments reported to CMS, 2019-2025
26 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.89 · 2021: $1,139 · 2022: $881 · 2023: $283 · 2024: $820 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,232.86 | 2021-2025 | Skyrizi, Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $802.20 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Ardelyx, INC. | $458.69 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $199.29 | 2022-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $171.33 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $170.10 | 2020-2022 | |
| Pfizer INC. | $170.06 | 2023-2025 | |
| Genzyme Corporation | $124.42 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $100.70 | 2022 | |
| Enterra Medical, INC. | $92.83 | 2024 | |
| Aimmune Therapeutics, INC. | $86.71 | 2024 | |
| Redhill Biopharma INC. | $76.45 | 2021-2025 | Talicia |
| Daiichi Sankyo INC. | $67.05 | 2021-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $64.18 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $63.66 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $59.10 | 2021-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $54.31 | 2025 | Voquezna |
| Amgen INC. | $42.79 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $31.44 | 2021 | |
| Vivus LLC | $28.40 | 2025 | Pancreaze |
| Ipsen Biopharmaceuticals, INC | $23.59 | 2024 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $21.42 | 2022 | |
| Lilly USA, LLC | $20.37 | 2025 | Mounjaro, Zepbound |
| Celgene Corporation | $18.28 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.71 | 2022 | |
| Lundbeck LLC | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tova Sofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.